Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sBOM:544742 +5.09%14 Gross Margin % is 41.28% as of Sep. 2025, which is 3% above its 10-year median of 40.13. GuruFocus rates BOM:544742 with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 941 Drug Manufacturers companies, Sai Parenteral's ranks worse than 62.81% on this metric.
The historical rank and industry rank for Sai Parenteral's's Gross Margin % or its related term are showing as below:
BOM:544742'
s Gross Margin % Range Over the Past 10 Years
Min: 38.24 Med: 40.13 Max: 45.4
Current: 41.28
During the past 3 years, the highestGross Margin % of Sai Parenteral's was 45.40%. The lowest was 38.24%. And the median was 40.13%.
BOM:544742's Gross Margin % is ranked worse than 62.81% of 941
companies
in the Drug Manufacturers industry
Industry Median: 48.42
vs BOM:544742: 41.28
Sai Parenteral's had a gross margin of 41.28% for the quarter that ended in Sep. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sai Parenteral's was 0.00% per year.
Sai Parenteral's (BOM:544742) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sai Parenteral's had a gross margin of 41.28% for the quarter that ended in Sep. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sai Parenteral's Gross Margin % Related Terms
Sai Parenteral's Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Gross Margin % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Gross Margin %
40.13
38.24
45.40
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Gross Margin %
0.00
0.00
0.00
41.28
BOM:544742 vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sai Parenteral's (BOM:544742) has a Gross Margin % of 41.28% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sai Parenteral's and its competitors. This is near median its historical median of 40.13. Over the past decade, Sai Parenteral's' Gross Margin % has ranged from 38.24 to 45.40. According to the industry distribution chart, Sai Parenteral's ranks #591 out of 941 companies in the Drug Manufacturers industry, placing it in the top 62.8%.
Is Sai Parenteral's' Gross Margin % too high?
Sai Parenteral's' current Gross Margin % of 41.28% is near median its 10-year median of 40.13. Over the past 10 years, this metric has ranged from a low of 38.24 to a high of 45.40. The Drug Manufacturers industry median Gross Margin % is 48.42. Sai Parenteral's' value of 41.28% is 14.7% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #591 out of 941 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #591 out of 941 companies for Gross Margin %. This places Sai Parenteral's in the lower half of its industry. The industry median Gross Margin % is 48.42. Sai Parenteral's' value of 41.28% is 14.7% below this benchmark. Historically, Sai Parenteral's' own Gross Margin % has ranged from 38.24 to 45.40 over the past decade. While the company's 10-year median is 40.13 vs. the industry median of 48.42, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.42, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Gross Margin % of 41.28% is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Gross Margin % is 41.28%, which is near median its own 10-year median of 40.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (BOM:544742) has a current Gross Margin % of 41.28%. The current Gross Margin % is 41.28%, which is near median its 10-year median of 40.13 and 14.7% below the Drug Manufacturers industry median of 48.42. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sai Parenteral's (BOM:544742), the current Gross Margin % is 41.28% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for BOM:544742
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544742 has been successfully added to your 
